A Survey on the Under-treatment of hypercholeSterolemia (EPHESUS Trial)

Hyperlipidemias Clinical Trial

— EPHESUS  

Official title:

Evaluation of Perceptions, Knowledge and Compliance With tHE Guidelines for Secondary Prevention in Real Life Practice: A Survey on the Under-treatment of hypercholeSterolemia (EPHESUS Trial)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02608645
• Other study ID #: EPHESUS trial
• Status: Not yet recruiting
• Phase: N/A
• First received: November 17, 2015
• Last updated: November 18, 2015
• Start date: November 2015
• Est. completion date: September 2016

Study information

• Verified date: November 2015
• Source: Mugla Sitki Koçman University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Turkey: Ethics Committee
• Study type: Observational

Clinical Trial Summary

In this study, within the secondary prevention group patients ( diabetes mellitus, coronary artery disease, peripheral artery disease, who have had events atherosclerotic cerebrovascular ) , statin use requirement , patients compliance and reaching target LDL-cholesterol levels (according to European guidelines ) will be evaluated.

Description:

In the majority of patients treated with lipid lowering agents are not under control in accordance with the lipids manual. In this study, within the secondary prevention group patients ( diabetes mellitus, coronary artery disease, peripheral artery disease, who have had events atherosclerotic cerebrovascular ) , statin use requirement , patients compliance and reaching target LDL-cholesterol levels (according to European guidelines ) will be evaluated.

The investigators' aim is to determine the role of education and knowledge in reaching target LDL cholesterol levels in these patients. İn addition , the investigators want to emphasize in high-risk patients who are receiving or not receiving cholesterol-lowering treatment what is their target values , (LDL < 100 mg / dL and high -risk patients with LDL < 70 mg / dL in very high-risk patients ) and to determine what is the rate of patients and to the importance of reaching their target cholesterol levels. İn addition ,to evaluate the patients habits of the using statin dose .After screening , physician treatment decisions and reasons will be documented.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 6000
• Est. completion date: September 2016
• Est. primary completion date: September 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with coronary artery disease (acute coronary syndromes, post- myocardial infarction patients, who have a history of percutaneous coronary intervention , history of coronary artery by-pass graft )

• Patients with carotid artery lesions or peripheral artery disease ,

• Type 2 diabetes mellitus patients

Exclusion Criteria:

• acute coronary syndrome in last 1 month

• pregnancy or the first 6 months postpartum

• ICU patients or emergency patients...etc.(other than polyclinic)

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Hypercholesterolemia
• Hyperlipidemias

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Mugla Sitki Koçman University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The number of patients with secondary prevention group receiving appropriate lipid lowering therapy		2 months	No